Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR

Journal of Psychopharmacology

Volumn 23, Issue 5, 2009, Pages 531-538

  Hewett, K ^a,d   Chrzanowski, W ^b   Schmitz, M ^c   Savela, A ^d   Milanova, V ^e   Gee, M ^a   Krishen, A ^f   Millen, L ^a   Leary, M O ^a   Modell, J ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Academy of Medicine   (Poland)

^c Department of Psychiatry   (Austria)

^d Klaara Keskus ^*  (United Kingdom)

^e UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^f GLAXOSMITHKLINE   (United States)

Author keywords

Bupropion XR; Depression; Venlafaxine XR

Indexed keywords

AMFEBUTAMONE; PLACEBO; UNCLASSIFIED DRUG; VENLAFAXINE; WELLBUTRIN XR;

ANXIETY; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAMILTON SCALE; HEART RATE; HUMAN; HYPERHIDROSIS; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; QRS COMPLEX; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REMISSION; SEIZURE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THIRST; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS;

EID: 67449143750     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108089602     Document Type: Article

References (27)

1. Alonso J., Angermeyer MC., Bernert S., Bruffaerts R., Brugha TS., Bryson H., (2004) Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 420: 21-27.
2. American Psychiatric Association (2000a) Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Arlington, VA, USA.
3. American Psychiatric Association (2000b) Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157 (Suppl). 1-45.
4. Blazer DG., (2003) Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci 58: 249-265. (Pubitemid 36307597)
5. Chrzanowski W., Rousseau R., Hewett K., Gee MD., Wightman D., Richard NE., (2006) Efficacy and safety of bupropion extended release in elderly patients with major depressive disorder. Eur Neuropscyhopharmacol 16: S315-S316.
6. Clayton AH., McGarvey EL., Clavet GJ., (1997) The Changes in Sexual Functioning Questionnaire (CSFQ). development, reliability, and validity. Psychopharmacol Bull 33: 731-745. (Pubitemid 28128129)
7. Coleman CC., Cunningham LA., Foster VJ., Batey SR., Donahue RM., Houser TL., (1999) Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 11: 205-215.
8. Coleman CC., King BR., Bolden-Watson C., Book MJ., Segraves RT., Richard N., (2001) A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 23: 1040-1058. (Pubitemid 32709626)
9. Croft H., Settle E., Houser T., Batey SR., Donahue RM., Ascher JA., (1999) A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 21: 643-658. (Pubitemid 29252088)
10. Fava M., Rush AJ., Thase ME., Clayton A., Stahl SM., Pradko JF., Johnston JA., (2005) 15 Years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 7: 106-113. (Pubitemid 41783226)
11. Geddes J.R., Freemantle N., Mason J., Eccles MP., Boynton J., (2000) SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev CD001851.
12. Kennedy SH., Andersen HF., Lam RW., (2006) Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 31: 122-131.
13. Kessler RC., Berglund P., Demler O., Jin R., Koretz D., Merikangas KR., (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095-3105. (Pubitemid 37432885)
14. Kobak KA., Greist JH., Jefferson JW., Mundt JC., Katzelnick DJ., (1999) Computerized assessment of depression and anxiety over the telephone using interactive voice response. MD Comput 16: 64-68.
15. Lineberry CG., Johnston JA., Raymond RN., Samara B., Feighner JP., Harto NE., (1990) A fixed-dose (300?mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry 51: 194-199. (Pubitemid 20159096)
16. Little JT., Ketter TA., Kimbrell TA., Dunn RT., Benson BE., Willis MW., (2005) Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biol Psychiatry 57: 220-228. (Pubitemid 40187365)
17. Modell JG., Rosenthal NE., Harriett AE., Krishen A., Asgharian A., Foster VJ., (2005) Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol Psychiatry 58: 658-667. (Pubitemid 41565581)
18. Rudolph RL., Derivan AT., (1996) The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 16 (Suppl. 2). 54S-59S.
19. Rush AJ., Trivedi MH., Wisniewski SR., Stewart JW., Nierenberg AA., Thase ME., (2006) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354: 1231-1242.
20. Stahl SM., (1998) Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J Clin Psychiatry 59 (Suppl. 18). 23-29. (Pubitemid 28538510)
21. Stahl SM., Grady MM., Moret C., Briley M., (2005) SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 10: 732-747. (Pubitemid 41443048)
22. Stahl SM., Pradko JF., Haight BR., Modell JG., Rockett CB., Learned-Coughlin S., (2004) A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 6: 159-166.
23. Thase ME; .,Clayton AH; .,Chrzanowski W; .,Wunderlich P; .,Hewett K; .,Haight BR; ., (2006a) Bupropion extended release and venlafaxine extended release for the treatment of depression: results from three multicenter trials. Eur Psychiatry 21(Suppl. 1): S168
24. Thase ME., Clayton AH., Haight BR., Thompson AH., Modell JG., Johnston JA., (2006b) A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol 26: 482-488. (Pubitemid 44401468)
25. Thase ME., Haight BR., Richard N., Rockett CB., Mitton M., Modell JG., (2005) Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 66: 974-981. (Pubitemid 41191788)
26. Weihs KL., Houser TL., Batey SR., Ascher JA., Bolden-Watson C., Donahue RM., (2002) Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry 51: 753-761. (Pubitemid 34450811)
27. Weihs KL., Settle EC., Batey SR., Houser TL., Donahue RM., Ascher JA., (2000) Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 61: 196-202. (Pubitemid 30214516)